secwatch.observer — SEC 8-K summary
======================================

Issuer:     EyePoint, Inc. (EYPT)
CIK:        0001314102
Form:       8-K
Filed at:   2026-08-17T12:50:21+00:00
Accession:  0001193125-26-353308
Event type: other_material
Sentiment:  negative
Materiality: 0.90
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

EyePoint DURAVYU LUGANO trial misses primary endpoint; secondary endpoints strong
--------------------------------------------------------------------------------

- Primary endpoint not met in full dataset; ad hoc analysis excluding 4% asymmetric cohort (9/211) showed non-inferiority to aflibercept (p=0.0096).
- 42% reduction in treatment burden vs aflibercept (p<0.0001); 76% supplement-free to Week 32, 54% to Week 56.
- 79% of DURAVYU patients received 0 or 1 supplement up to Week 56; supplement-free BCVA non-inferior (p=0.0035).
- LUCIA topline expected Q4 2026; NDA filing planned 1H 2027; DME trials COMO/CAPRI topline Q4 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/0001193125-26-353308-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1314102/000119312526353308/eypt-20260817.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-353308

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer